In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Wall Street thinks these struggling stocks are undervalued, and certain analysts expect monster gains in the next year.

Is Pete Bevacqua finished yet? He's been airing his grievances for several days now and his frequent target has been the ACC, ...

The Democratic National Committee launches ad campaign targeting four vulnerable Republican senators ahead of crucial Senate ...

Netflix, O'Reilly Automotive, Lucid Group, Fastenal, and Interactive Brokers -- can skyrocket in the new year, if the ...

Opera delivered 30% revenue growth and above-market margins, but recent margin erosion warrants close monitoring. Read why ...

The Trump administration may have softened its language on China to maintain a truce in their trade war, but Congress is ...

Alzheimer’s disease (AD) imposes a substantial clinical and societal burden, yet currently approved symptomatic therapies do ...

Secretary of State Marco Rubio has ordered diplomatic correspondence to stop using the Calibri font and return to the more ...

Shopify launched its latest advertising business line on Wednesday, called the Shopify Product Network. The Product Network ...

The central pathology of APOEε4 involves a vicious cycle of lipid metabolism disorders and neuroinflammation. Consequently, upregulating lipidation transporters, such as ABCA1, to improve APOEε4's ...

Alphabet Inc. (NASDAQ: GOOGL) is one of the AI Stocks on the Market’s Radar . On December 5, Truist Securities raised its ...